Vivoryon Therapeutics N.V. shows positive results in Phase 2 study for varoglutamstat, focusing on kidney disease

From GlobeNewswire: 2024-09-12 01:00:00

Vivoryon Therapeutics N.V. has made significant progress in H1 2024, focusing on developing varoglutamstat to improve kidney function in patients with kidney disease. Positive results in a Phase 2 study showed a higher treatment benefit for varoglutamstat, prompting plans for further studies in diabetic kidney disease. Insights gained from the study will inform future developments.

The VIVIAD Phase 2b study demonstrated varoglutamstat’s potential in improving kidney function, leading to a strategic shift towards inflammatory and fibrotic diseases. Plans include a proposed Phase 2 study in diabetic kidney disease, analysis of VIVA-MIND Phase 2 results in early Alzheimer’s disease, and pursuit of business and financing opportunities to advance research.

Varoglutamstat is a powerful inhibitor of QPCT and QPCTL enzymes, preventing pyroglutamate formation and targeting disease drivers in conditions like inflammation and fibrosis. The drug showcased a significant increase in eGFR, a key kidney function indicator, in patients with early AD. Results highlighted varoglutamstat’s potential in treating kidney disorders.



Read more at GlobeNewswire:: Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked